Low to Moderate Sugar-sweetened Beverage Consumption Impairs Glucose and Lipid Metabolism and Promotes Inflammation in Healthy Young Men: a Randomized Controlled Trial
Overview
Authors
Affiliations
Background: Sugar-sweetened beverages (SSBs) have unfavorable effects on glucose and lipid metabolism if consumed in high quantities by obese subjects, but the effect of lower doses in normal-weight subjects is less clear.
Objective: The aim was to investigate the effects of SSBs consumed in small to moderate quantities for 3 wk on LDL particle distribution and on other parameters of glucose and lipid metabolism as well as on inflammatory markers in healthy young men.
Design: Twenty-nine subjects were studied in a prospective, randomized, controlled crossover trial. Six 3-wk interventions were assigned in random order as follows: 600 mL SSBs containing 1)40 g fructose/d [medium fructose (MF)], 2) 80 g fructose/d [high fructose (HF)], 3) 40 g glucose/d [medium glucose (MG)], 4) 80 g glucose/d [high glucose (HG)], 5) 80 g sucrose/d [high sucrose (HS)], or 6) dietary advice to consume low amounts of fructose. Outcome parameters were measured at baseline and after each intervention.
Results: LDL particle size was reduced after HF by -0.51 nm (95% CI: -0.19, -0.82 nm) and after HS by -0.43 nm (95% CI: -0.12, -0.74; P < 0.05 for both). Similarly, a more atherogenic LDL subclass distribution was seen when fructose-containing SSBs were consumed (MF, HF, and HS: P < 0.05). Fasting glucose and high-sensitivity C-reactive protein (hs-CRP) increased significantly after all interventions (by 4-9% and 60-109%, respectively; P < 0.05); leptin increased during interventions with SSBs containing glucose only (MG and HG: P < 0.05).
Conclusion: The present data show potentially harmful effects of low to moderate consumption of SSBs on markers of cardiovascular risk such as LDL particles, fasting glucose, and hs-CRP within just 3 wk in healthy young men, which is of particular significance for young consumers. This trial was registered at clinicaltrials.gov as NCT01021969.
Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, Weber D Lipids Health Dis. 2025; 24(1):88.
PMID: 40057729 PMC: 11889781. DOI: 10.1186/s12944-025-02500-1.
Nouri M, Ebrahimi Z, Shateri Z, Faghih S BMC Res Notes. 2025; 18(1):59.
PMID: 39920828 PMC: 11806892. DOI: 10.1186/s13104-025-07132-3.
Ma Q, Zhang Y, Zhang D, Liu C, Zhu W, Wang G Front Endocrinol (Lausanne). 2025; 15:1417840.
PMID: 39866739 PMC: 11757130. DOI: 10.3389/fendo.2024.1417840.
Mendoza K, Barquera S, Tobias D Diabetologia. 2025; 68(3):495-506.
PMID: 39825911 DOI: 10.1007/s00125-025-06358-x.
Xia T, Yuan Q, Zhang Y, Shan G BMC Public Health. 2025; 25(1):88.
PMID: 39780125 PMC: 11707922. DOI: 10.1186/s12889-024-21249-3.